168 related articles for article (PubMed ID: 30496647)
1. Sanofi vows to limit price hikes- but will it make much difference?
Kacik A
Mod Healthc; 2017 May; 47(20):12. PubMed ID: 30496647
[TBL] [Abstract][Full Text] [Related]
2. Drug price hikes and shortages have similar roots, experts say.
Traynor K
Am J Health Syst Pharm; 2016 Feb; 73(3):98-9. PubMed ID: 26796898
[No Abstract] [Full Text] [Related]
3. Exploring the rise in American pharmaceutical prices.
Marwaha A
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
[No Abstract] [Full Text] [Related]
4. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
5. American pharmaceutical prices.
Alagona P
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
[No Abstract] [Full Text] [Related]
6. Pricing pain: relief in sight on drug costs?
J Am Health Policy; 1992; 2(6):28-31. PubMed ID: 10122415
[TBL] [Abstract][Full Text] [Related]
7. Prescription drug prices in Canada.
Gross D
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
[No Abstract] [Full Text] [Related]
8. Meeting resistance. Express Scripts-Medco deal called anti-competitive.
Lee J
Mod Healthc; 2011 Aug; 41(32):10-1. PubMed ID: 21879692
[No Abstract] [Full Text] [Related]
9. The Canadians are killing us.
Struble RA
Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58-9. PubMed ID: 12592981
[No Abstract] [Full Text] [Related]
10. [The new reference prices: an opportunity for efficient management of medication].
Ausejo Segura M
Aten Primaria; 2005 Feb; 35(2):64-6. PubMed ID: 15727746
[No Abstract] [Full Text] [Related]
11. The future of prescription drug cost-sharing: real progress or dropped opportunity?
Fairman KA
J Manag Care Pharm; 2008; 14(1):70-82. PubMed ID: 18240885
[No Abstract] [Full Text] [Related]
12. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
Robinson JC
N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
[No Abstract] [Full Text] [Related]
13. The effect of changes in treatment patterns on drug expenditure.
Gerdtham UG; Johannesson M; Gunnarsson B; Marcusson M; Henriksson F
Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):127-34. PubMed ID: 10176147
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
Darba J
Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
[No Abstract] [Full Text] [Related]
15. Should the US allow prescription drug reimports from Canada?
Pecorino P
J Health Econ; 2002 Jul; 21(4):699-708. PubMed ID: 12146598
[TBL] [Abstract][Full Text] [Related]
16. Copayment coupons undermine formularies.
Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
[No Abstract] [Full Text] [Related]
17. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
18. A Policy-Driven Perspective on Rising Drug Costs in Dermatology.
Nguyen HP; Forman HP
JAMA Dermatol; 2016 Jun; 152(6):625-6. PubMed ID: 27008060
[No Abstract] [Full Text] [Related]
19. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
20. How insurers' bargaining power affects drug prices in Medicare Part D.
Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
